TENX insider filings
TENAX THERAPEUTICS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-21. Screen TENX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 14 legs across 7 filings by 5 insiders — 3,688,574 shares, $6,396,312 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 900,000 shares @ $1.78 ($1,604,160) by ADAR1 Capital Management, LLC, filed 2026-09-08.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC — 10% owner & Schneeberger Daniel — 10% owner | 4 | 10 legs · 3,619,049 sh · $6,263,483 | — | — |
| Doogan Declan — Director | 1 | 1 leg · 53,000 sh · $101,760 | — | — |
| Giordano Christopher Thomas — CEO, Director | 1 | 2 legs · 10,850 sh · $20,087 | — | — |
| STAAB THOMAS R II — Chief Financial Officer | 1 | 1 leg · 5,675 sh · $10,981 | — | — |
Recent insider filings — TENAX THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-21 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 336,528 @ $1.51 · Purchase (P): 254,342 @ $1.60 · Purchase (P): 331,979 @ $1.66 | EDGAR |
| 2026-09-17 | 4 | Doogan Declan — Director | Purchase (P): 53,000 @ $1.92 | EDGAR |
| 2026-09-15 | 4 | Giordano Christopher Thomas — CEO, Director | Purchase (P): 6,000 @ $1.88 · Purchase (P): 4,850 @ $1.82 | EDGAR |
| 2026-09-15 | 4 | STAAB THOMAS R II — Chief Financial Officer | Purchase (P): 5,675 @ $1.94 | EDGAR |
| 2026-09-08 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 900,000 @ $1.78 | EDGAR |
| 2026-09-02 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 403,571 @ $1.79 · Purchase (P): 179,058 @ $1.80 · Purchase (P): 187,704 @ $1.80 | EDGAR |
| 2026-08-24 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 202,124 @ $1.78 · Purchase (P): 716,369 @ $1.77 · Purchase (P): 107,374 @ $1.75 | EDGAR |
| 2026-07-14 | 4 | Giordano Christopher Thomas — CEO, Director | Option exercise (M): 219 @ $3.55 · Option exercise (M): 8,500 @ $5.94 · Option exercise (M): 219 (derivative) @ $0 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | STAAB THOMAS R II — Chief Financial Officer | Grant/award (A): 10,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | MCGAULEY THOMAS — Interim CFO | Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Giordano Christopher Thomas — CEO, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Rich Stuart — Chief Medical Officer, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Hunter Robyn — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Doogan Declan — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Davidson Michael H. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Almenoff June Sherie — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | PROEHL GERALD T — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Rich Stuart — Chief Medical Officer, Director | Purchase (P): 2,500 @ $10.10 · Purchase (P): 2,500 @ $10.22 | EDGAR |
| 2025-12-05 | 4 | Rich Stuart — Chief Medical Officer, Director | Purchase (P): 1,000 @ $9.01 · Purchase (P): 1,500 @ $9.08 · Purchase (P): 2,500 @ $9.20 | EDGAR |
| 2025-11-20 | 4 | Giordano Christopher Thomas — CEO, Director | Purchase (P): 1,612 @ $7.75 · Purchase (P): 455 @ $7.51 · Purchase (P): 538 @ $7.59 | EDGAR |
| 2025-11-20 | 4/A | Almenoff June Sherie — Director | Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52 | EDGAR |
| 2025-11-19 | 4 | MCGAULEY THOMAS — Interim CFO | Purchase (P): 2,000 @ $7.34 · Purchase (P): 1,000 @ $7.35 · Purchase (P): 5,000 @ $7.23 | EDGAR |
| 2025-11-19 | 4 | Almenoff June Sherie — Director | Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52 | EDGAR |
| 2025-07-03 | 4 | Hunter Robyn — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Doogan Declan — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Davidson Michael H. — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Almenoff June Sherie — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | PROEHL GERALD T — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Giordano Christopher Thomas — CEO, Director | Grant/award (A): 1,400,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Rich Stuart — Chief Medical Officer, Director | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Dellora Investments LP | Holdings only — no transactions reported | EDGAR |
| 2024-12-12 | 4 | Giordano Christopher Thomas — CEO, Director | Grant/award (A): 1,250,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Rich Stuart — Chief Medical Officer, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Hunter Robyn — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Doogan Declan — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Davidson Michael H. — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Almenoff June Sherie — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | PROEHL GERALD T — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-08-08 | 4 | Davidson Michael H. — Director | Purchase (P): 2,500 · Purchase (P): 47,500 (derivative) · Purchase (P): 25,000 (derivative) | EDGAR |
| 2024-08-08 | 4 | PROEHL GERALD T — Director | Purchase (P): 1,666 · Purchase (P): 31,654 (derivative) · Purchase (P): 16,660 (derivative) | EDGAR |
| 2024-05-21 | 4 | Giordano Christopher Thomas — CEO, Director | Grant/award (A): 437 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Rich Stuart — Chief Medical Officer, Director | Grant/award (A): 119 (derivative) @ $0 | EDGAR |
| 2022-09-23 | 4 | Rich Stuart — Chief Medical Officer, Director, 10% owner | Gift (G): 1,909,585 @ $0 · Gift (G): 1,909,585 @ $0 | EDGAR |
| 2022-08-12 | 4 | Doogan Declan — Director, 10% owner | Gift (G): 567,871 @ $0 · Gift (G): 567,871 @ $0 | EDGAR |
| 2022-06-10 | 4 | Rich Stuart — Chief Medical Officer, Director, 10% owner | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Hunter Robyn — Director | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Doogan Declan — Director, 10% owner | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Davidson Michael H. — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Almenoff June Sherie — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | PROEHL GERALD T — Director | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — TENAX THERAPEUTICS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TENX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs